Clinical Trial Update: Lysosomal Acid Lipase Deficiency in Risk Groups

View source ↗

Summary

AstraZeneca is recruiting participants for a clinical trial addressing lysosomal acid lipase deficiency in at-risk groups.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lysosomal Acid Lipase Deficiency

Drugs mentioned

• KANUMA (Sebelipase alfa)

Snippet

Sponsor: AstraZeneca | Conditions: Lysosomal Acid Lipase Deficiency | Status: RECRUITING